Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.

Ashley Jackson^1,2, Pradeep S Virdee¹, Sharon Tonner¹, Jason L Oke¹, Rafael Perera¹, Kaveh Riahi³, Sara Hiom³, Harpal Kumar³, F D Richard Hobbs¹, Mark R Middleton⁴, Brian D Nicholson¹

¹Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

²Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

³GRAIL Bio UK, Ltd., London, UK.

⁴Department of Oncology, University of Oxford, Oxford, UK.

PubMed PMC DOI PDF

Abstract

BACKGROUND: The observational SYMPLIFY study reported the accuracy of a multi-cancer early detection (MCED) test in a referred symptomatic population. We explore how the MCED test may contribute to a faster or more efficient diagnosis if acted upon. METHODS: We reviewed all cancers diagnosed in SYMPLIFY (ISRCTN10226380) using data collected at study sites plus two years of cancer registry data. A…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.